The Medicines for Malaria Venture, a large international group working on new pharma to combat this deadly parasite has announced a new antimalarial compound active against Plasmodium at different stages of its lifecycle. This property might make it able to resist the emergence of resistance in the disease. Michael Riscoe and his colleagues at the Oregon Health and Science University, USA, are part of MMV. The drug, ELQ-300, targets parasitic mitochondria, the primary function of which is to produce the pyrimidine building blocks for DNA rather than the more familiar powerhouse function of our cells. The new drug inhibits pyrimidine synthesis halting parasite reproduction.
Resistance is not futile